candesartan has been researched along with Diabetes Mellitus, Adult-Onset in 80 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | 9.16 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| "Individual and pooled results of the 3 trials showed that candesartan had little effect on risk for microalbuminuria (pooled hazard ratio, 0." | 9.14 | Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2009) |
| "Switching from candesartan to telmisartan in obese subjects increases serum adiponectin and improves both insulin resistance and oxidative stress, while these effects were not statistically apparent in the total patient population." | 9.14 | Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. ( Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M, 2010) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 9.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "We assessed the impact of candesartan versus placebo on the development of diabetes, a predefined secondary outcome in a randomized, controlled, double-blind study involving 5436 of the 7601 patients with heart failure, irrespective of ejection fraction, who did not have a diagnosis of diabetes at entry into the trial." | 9.11 | Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. ( Gerstein, HC; Granger, CB; McMurray, JV; Olofsson, B; Ostergren, JB; Pfeffer, MA; Probstfield, J; Swedberg, K; Yusuf, S, 2005) |
| "Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes." | 9.09 | Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. ( Cooper, ME; Mogensen, CE; Neldam, S; Oren, S; Tikkanen, I; Viskoper, R; Watts, RW, 2000) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "This study investigated whether the angiotensin II type-1 receptor blocker (ARB) candesartan affects markers of oxidative stress in type 2 diabetes mellitus (DM) patients with essential hypertension (EH)." | 7.79 | Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. ( Miura, Y; Mizuno, K; Ono, Y; Takahashi, M; Watanabe, T, 2013) |
| " Throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism." | 7.76 | The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. ( Tsutsumi, E; Yamaguchi, K, 2010) |
| "Candesartan treatment (10 or 30 mg/kg; orally) was initiated one day post CLI and thereafter once daily for up to 14 days." | 5.91 | Candesartan protects against unilateral peripheral limb ischemia in type-2 diabetic rats: Possible contribution of PI3K-Akt-eNOS-VEGF angiogenic signaling pathway. ( Abdelaziz, RR; Elshaer, SL; Khaled, S; Suddek, GM, 2023) |
| "Given the association of diabetic retinopathy (DR) and kidney disease, we investigated the urinary peptidome to presence and deterioration of DR in a post hoc analysis of trials investigating the effect of candesartan on progression of DR in type 1 and type 2 diabetes, respectively." | 5.41 | Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials. ( Hansen, TW; He, T; Magalhães, P; Mischak, H; Rossing, P; Rotbain Curovic, V, 2021) |
| "Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 5.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
| "Candesartan was orally administered to 12-week-old rats for 21 days, and age-matched rats without the agent were used as the respective controls." | 5.31 | Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. ( Daimon, M; Hirata, A; Igarashi, M; Kato, T; Ohnuma, H; Tominaga, M; Tsuchiya, H; Yamaguchi, H, 2001) |
| " Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | 5.16 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| "To study the association between baseline retinal microaneurysm score and progression and regression of diabetic retinopathy, and response to treatment with candesartan in people with diabetes." | 5.15 | Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme. ( Aldington, S; Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| "The aim of this study is to compare the effects of candesartan and olmesartan on insulin sensitivity-related parameters, before and after antihypertensive therapy." | 5.14 | Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA, 2010) |
| "Individual and pooled results of the 3 trials showed that candesartan had little effect on risk for microalbuminuria (pooled hazard ratio, 0." | 5.14 | Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2009) |
| "In a previous study involving 18 hypertensive patients with type 2 diabetes mellitus, we found that replacement of valsartan and candesartan by telmisartan significantly improved insulin sensitivity and significantly increased serum adiponectin levels in the patients." | 5.14 | Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. ( Kondo, K; Nomura, Y; Oiso, Y; Ozaki, N; Sobajima, H, 2010) |
| "Switching from candesartan to telmisartan in obese subjects increases serum adiponectin and improves both insulin resistance and oxidative stress, while these effects were not statistically apparent in the total patient population." | 5.14 | Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. ( Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M, 2010) |
| "Type 2 diabetic patients with hypertension received either ARB (candesartan), or a calcium channel blocker (CCB; amlodipine or nifedipine) for 12 weeks." | 5.13 | Angiotensin II type-I receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients. ( Ishii, H; Tsukada, T; Yoshida, M, 2008) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 5.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "To assess and compare the long-term effects of the combination of candesartan and lisinopril with high-dose lisinopril on systolic blood pressure in patients with hypertension and diabetes." | 5.11 | Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. ( Andersen, NH; Eiskjaer, H; Hansen, KW; Helleberg, K; Knudsen, ST; Mogensen, CE; Poulsen, PL; Poulsen, SH, 2005) |
| "We assessed the impact of candesartan versus placebo on the development of diabetes, a predefined secondary outcome in a randomized, controlled, double-blind study involving 5436 of the 7601 patients with heart failure, irrespective of ejection fraction, who did not have a diagnosis of diabetes at entry into the trial." | 5.11 | Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. ( Gerstein, HC; Granger, CB; McMurray, JV; Olofsson, B; Ostergren, JB; Pfeffer, MA; Probstfield, J; Swedberg, K; Yusuf, S, 2005) |
| "The optimal dose of candesartan is 16 mg daily for renoprotection, as reflected by short-term reduction in albuminuria, in hypertensive type 2 diabetic patients with nephropathy." | 5.10 | Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. ( Carstensen, B; Christensen, PK; Hansen, BV; Parving, HH; Rossing, K, 2003) |
| "Perindopril and candesartan both effectively lowered blood pressure in this group of patients with mild hypertension and type 2 DM." | 5.10 | A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R, 2003) |
| "Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes." | 5.09 | Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. ( Cooper, ME; Mogensen, CE; Neldam, S; Oren, S; Tikkanen, I; Viskoper, R; Watts, RW, 2000) |
| "The main objective of the CALM (Candesartan And Lisinopril Microalbuminuria) study is to assess the effect of a dual blockade of the renin-angiotensin system--using both an angiotensin converting enzyme inhibitor (ACE-I) and an angiotensin II type 1 receptor blocker--in patients with type 2 diabetes, high blood pressure and microalbuminuria." | 5.09 | [Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy]. ( Philips, JC; Scheen, AJ; Weekers, L, 2001) |
| "Trandolapril+candesartan appears to be the most efficacious intervention for reducing albuminuria for normotensive patients, while fosinopril+amlodipine appears to be the most efficacious intervention for reducing albuminuria for hypertensive patients." | 4.95 | Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis. ( Feng, Y; Huang, R; Li, X; Melgiri, ND; Qin, X; Sun, Y; Wang, Y, 2017) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "The introduction of Angiotensin II receptor blockers (ARB) in 1995 was another milestone in the pharmacological management of hypertension." | 4.82 | [Angiotensin II receptor blockers--evidence along the cardiovascular continuum]. ( Battegay, E; Zeller, A, 2005) |
| "We performed a post hoc analysis in the Diabetic Retinopathy Candesartan Trials (DIRECT-Protect 2 study), a multi centric randomized clinical controlled trial." | 3.85 | Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. ( Bilous, R; Chaturvedi, N; de Zeeuw, D; Fuller, J; Klein, R; Lambers Heerspink, H; Lindhardt, M; Mischak, H; Orchard, T; Parving, HH; Persson, F; Porta, M; Rossing, P; Stalmach, A; Zürbig, P, 2017) |
| "This study investigated whether the angiotensin II type-1 receptor blocker (ARB) candesartan affects markers of oxidative stress in type 2 diabetes mellitus (DM) patients with essential hypertension (EH)." | 3.79 | Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. ( Miura, Y; Mizuno, K; Ono, Y; Takahashi, M; Watanabe, T, 2013) |
| " Throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism." | 3.76 | The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. ( Tsutsumi, E; Yamaguchi, K, 2010) |
| "Olmesartan is a promising ARB for BP control in hypertensive type 2 diabetics." | 2.79 | Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study. ( Daikuhara, H; Fukunaga, K; Ohshima, T, 2014) |
| "Sixty-eight diabetic nephropathy patients with microalbuminuria were randomly allocated to 1 of 4 treatment groups: losartan 100 mg/day (group A), candesartan 12 mg/day (group B), olmesartan 40 mg/day (group C), or telmisartan 80 mg/day (group D)." | 2.75 | Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy. ( Fujiwara, N; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y, 2010) |
| "Treatment with candesartan in type 2 diabetic patients with mild to moderate retinopathy might induce improvement of retinopathy." | 2.73 | Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2008) |
| "Aldosterone is an important pathogenetic factor, independent of the renin-angiotensin system in cardiovascular and renal disease." | 2.73 | Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. ( Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T, 2007) |
| "In vivo, 56 patients with both type 2 diabetes and hypertension were enrolled and randomized to receive either telmisartan (40 mg) or candesartan (8 mg) for 3 months." | 2.73 | Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. ( Ano, N; Atsuda, K; Inoue, G; Irie, J; Kitaoka, A; Shiono, K; Toda, K; Yamada, S, 2008) |
| "Twenty-four asymptomatic patients with type 2 diabetes were randomly assigned to temocapril (2 mg/d) or candesartan (8 mg/d)." | 2.72 | Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist. ( Daimon, M; Hasegawa, R; Himi, T; Kawata, T; Komuro, I; Sekine, T; Teramoto, K; Toyoda, T; Uchida, D; Yamamoto, K; Yoshida, K, 2006) |
| "In patients with type 2 diabetes and nephropathy, dual blockade of the renin system with an angiotensin-converting enzyme inhibitor and angiotensin receptor blocker significantly reduces albuminuria and, thus, may be renoprotective even when the doses of the agents are reduced by one half." | 2.71 | Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. ( Fujisawa, T; Ikegami, H; Kawabata, Y; Nishino, M; Noso, S; Ogihara, T; Ono, M, 2005) |
| "Candesartan treatment in macroalbuminuric patients significantly changed 15 of the 113 polypeptides in the diabetic renal damage pattern toward levels in normoalbuminuric patients." | 2.71 | Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. ( Christensen, PK; Hillmann, M; Kaiser, T; Mischak, H; Parving, HH; Rossing, K; Walden, M, 2005) |
| "Among the 1,281 patients with incident cancer and 5,104 controls, 333 (26." | 2.47 | Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. ( Chang, CH; Lai, MS; Lin, JW; Wu, LC, 2011) |
| "Candesartan treatment (10 or 30 mg/kg; orally) was initiated one day post CLI and thereafter once daily for up to 14 days." | 1.91 | Candesartan protects against unilateral peripheral limb ischemia in type-2 diabetic rats: Possible contribution of PI3K-Akt-eNOS-VEGF angiogenic signaling pathway. ( Abdelaziz, RR; Elshaer, SL; Khaled, S; Suddek, GM, 2023) |
| "Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 1.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
| "Treatment with candesartan markedly increased mRNA expression of angiotensin II type-2 receptor and methyl methanesulfonate sensitive-2 in the brain in KK-A(y) mice, determined by quantitative RT-PCR." | 1.34 | Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. ( Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2007) |
| "Treatment with candesartan attenuated all of these changes and prevented significant albuminuria." | 1.32 | Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. ( Fan, Q; Gohda, T; Gu, L; Horikoshi, S; Kobayashi, M; Liao, J; Suzuki, Y; Tomino, Y; Wang, LN; Yamashita, M, 2004) |
| "Candesartan was orally administered to 12-week-old rats for 21 days, and age-matched rats without the agent were used as the respective controls." | 1.31 | Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. ( Daimon, M; Hirata, A; Igarashi, M; Kato, T; Ohnuma, H; Tominaga, M; Tsuchiya, H; Yamaguchi, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 47 (58.75) | 29.6817 |
| 2010's | 30 (37.50) | 24.3611 |
| 2020's | 3 (3.75) | 2.80 |
| Authors | Studies |
|---|---|
| Khaled, S | 1 |
| Abdelaziz, RR | 1 |
| Suddek, GM | 1 |
| Elshaer, SL | 1 |
| Tchernev, G | 1 |
| Rotbain Curovic, V | 1 |
| Magalhães, P | 1 |
| He, T | 1 |
| Hansen, TW | 1 |
| Mischak, H | 3 |
| Rossing, P | 2 |
| Suzuki, H | 2 |
| Sakamoto, M | 2 |
| Hayashi, T | 2 |
| Iuchi, H | 2 |
| Ohashi, K | 1 |
| Isaka, T | 2 |
| Sakamoto, N | 2 |
| Kayama, Y | 2 |
| Tojo, K | 2 |
| Yoshimura, M | 2 |
| Utsunomiya, K | 2 |
| Ono, Y | 1 |
| Mizuno, K | 1 |
| Takahashi, M | 1 |
| Miura, Y | 2 |
| Watanabe, T | 1 |
| Daikuhara, H | 2 |
| Fukunaga, K | 1 |
| Ohshima, T | 1 |
| Hasvold, LP | 1 |
| Bodegård, J | 1 |
| Thuresson, M | 1 |
| Stålhammar, J | 1 |
| Hammar, N | 1 |
| Sundström, J | 1 |
| Russell, D | 1 |
| Kjeldsen, SE | 1 |
| Luo, H | 1 |
| Wang, X | 1 |
| Wang, J | 1 |
| Chen, C | 1 |
| Wang, N | 1 |
| Xu, Z | 1 |
| Chen, S | 1 |
| Zeng, C | 1 |
| Lindhardt, M | 1 |
| Persson, F | 1 |
| Zürbig, P | 1 |
| Stalmach, A | 1 |
| de Zeeuw, D | 1 |
| Lambers Heerspink, H | 1 |
| Klein, R | 5 |
| Orchard, T | 4 |
| Porta, M | 5 |
| Fuller, J | 4 |
| Bilous, R | 5 |
| Chaturvedi, N | 4 |
| Parving, HH | 8 |
| Huang, R | 1 |
| Feng, Y | 1 |
| Wang, Y | 1 |
| Qin, X | 1 |
| Melgiri, ND | 1 |
| Sun, Y | 1 |
| Li, X | 1 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Yamada, S | 1 |
| Ano, N | 1 |
| Toda, K | 1 |
| Kitaoka, A | 1 |
| Shiono, K | 1 |
| Inoue, G | 1 |
| Atsuda, K | 1 |
| Irie, J | 1 |
| Mitchell, P | 1 |
| Wong, TY | 1 |
| Sjølie, AK | 5 |
| Fukumoto, M | 1 |
| Takai, S | 1 |
| Ishizaki, E | 1 |
| Sugiyama, T | 1 |
| Oku, H | 1 |
| Jin, D | 1 |
| Sakaguchi, M | 1 |
| Sakonjo, H | 1 |
| Ikeda, T | 1 |
| Miyazaki, M | 1 |
| Eriksson, JW | 1 |
| Jansson, PA | 1 |
| Carlberg, B | 1 |
| Hägg, A | 1 |
| Kurland, L | 1 |
| Svensson, MK | 1 |
| Ahlström, H | 1 |
| Ström, C | 1 |
| Lönn, L | 1 |
| Ojbrandt, K | 1 |
| Johansson, L | 1 |
| Lind, L | 1 |
| Ishii, H | 1 |
| Tsukada, T | 1 |
| Yoshida, M | 1 |
| Ikeda, H | 1 |
| Hamamoto, Y | 1 |
| Honjo, S | 1 |
| Nabe, K | 1 |
| Wada, Y | 1 |
| Koshiyama, H | 1 |
| Yamauchi, T | 1 |
| Kadowaki, T | 1 |
| Shimizu, H | 1 |
| Uehara, Y | 1 |
| Ohsaki, A | 1 |
| Okada, S | 1 |
| Mori, M | 1 |
| Saruta, T | 4 |
| Hayashi, K | 1 |
| Ogihara, T | 5 |
| Nakao, K | 4 |
| Fukui, T | 1 |
| Fukiyama, K | 1 |
| Wright, AD | 1 |
| Dodson, PM | 1 |
| Fukuda, M | 1 |
| Nakamura, T | 2 |
| Kataoka, K | 1 |
| Nako, H | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Derosa, G | 4 |
| Maffioli, P | 2 |
| Salvadeo, SA | 2 |
| Ferrari, I | 2 |
| Gravina, A | 2 |
| Mereu, R | 2 |
| Palumbo, I | 2 |
| D'Angelo, A | 2 |
| Cicero, AF | 4 |
| Yasuno, S | 3 |
| Ueshima, K | 3 |
| Oba, K | 2 |
| Fujimoto, A | 4 |
| Hirata, M | 2 |
| Yamaguchi, K | 1 |
| Tsutsumi, E | 1 |
| Ozaki, N | 2 |
| Nomura, Y | 1 |
| Sobajima, H | 1 |
| Kondo, K | 1 |
| Oiso, Y | 2 |
| Fogari, E | 1 |
| Fujiwara, N | 1 |
| Sato, E | 1 |
| Ueda, Y | 1 |
| Sugaya, T | 1 |
| Koide, H | 1 |
| Barrios, V | 2 |
| Escobar, C | 2 |
| Calderon, A | 2 |
| Watanabe, M | 1 |
| Inukai, K | 1 |
| Sumita, T | 1 |
| Ikebukuro, K | 1 |
| Ito, D | 1 |
| Kurihara, S | 1 |
| Ono, H | 1 |
| Awata, T | 1 |
| Katayama, S | 1 |
| Pavlatou, MG | 2 |
| Mastorakos, G | 2 |
| Margeli, A | 1 |
| Kouskouni, E | 1 |
| Tentolouris, N | 1 |
| Katsilambros, N | 2 |
| Chrousos, GP | 2 |
| Papassotiriou, I | 2 |
| De Rosa, ML | 1 |
| Dodson, P | 1 |
| Hobbs, FR | 1 |
| Aldington, S | 1 |
| Okura, T | 1 |
| Kojima, M | 1 |
| Machida, H | 1 |
| Sugiyama, M | 1 |
| Kato, T | 2 |
| Komada, T | 1 |
| Miyazaki, T | 1 |
| Ninomiya, T | 1 |
| Ichikawa, T | 1 |
| Nakatani, K | 1 |
| Watanabe, Y | 1 |
| Dohi, Y | 1 |
| Ito, M | 1 |
| Kimura, G | 1 |
| Chang, CH | 1 |
| Lin, JW | 1 |
| Wu, LC | 1 |
| Lai, MS | 1 |
| Guan, W | 1 |
| Kozak, A | 1 |
| Fagan, SC | 1 |
| Kikuchi, F | 1 |
| Ishida, T | 1 |
| Park, S | 1 |
| Bivona, BJ | 1 |
| Ford, SM | 1 |
| Xu, S | 1 |
| Kobori, H | 1 |
| de Garavilla, L | 1 |
| Harrison-Bernard, LM | 1 |
| Jesmin, S | 1 |
| Hattori, Y | 1 |
| Sakuma, I | 1 |
| Mowa, CN | 1 |
| Kitabatake, A | 1 |
| Mansour, G | 1 |
| Mansour, J | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Tokudome, G | 1 |
| Horiguchi, M | 1 |
| Hayashi, H | 1 |
| Kobayashi, H | 1 |
| Ishikawa, M | 1 |
| Hosoya, T | 1 |
| Rossing, K | 3 |
| Christensen, PK | 2 |
| Hansen, BV | 1 |
| Carstensen, B | 1 |
| Mugellini, A | 2 |
| Ciccarelli, L | 2 |
| Fogari, R | 3 |
| Jacobsen, P | 1 |
| Pietraszek, L | 1 |
| Sidorenko, BA | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Stetsenko, TM | 1 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Evans, L | 1 |
| Fan, Q | 1 |
| Liao, J | 1 |
| Kobayashi, M | 1 |
| Yamashita, M | 1 |
| Gu, L | 1 |
| Gohda, T | 1 |
| Suzuki, Y | 1 |
| Wang, LN | 1 |
| Horikoshi, S | 1 |
| Tomino, Y | 1 |
| Schram, MT | 2 |
| van Ittersum, FJ | 2 |
| Spoelstra-de Man, A | 1 |
| van Dijk, RA | 2 |
| Schalkwijk, CG | 1 |
| Ijzerman, RG | 2 |
| Twisk, JW | 2 |
| Stehouwer, CD | 2 |
| Andersen, NH | 2 |
| Poulsen, PL | 2 |
| Knudsen, ST | 2 |
| Poulsen, SH | 2 |
| Eiskjaer, H | 2 |
| Hansen, KW | 2 |
| Helleberg, K | 2 |
| Mogensen, CE | 3 |
| Fujisawa, T | 1 |
| Ikegami, H | 1 |
| Ono, M | 1 |
| Nishino, M | 1 |
| Noso, S | 1 |
| Kawabata, Y | 1 |
| Yamamoto, N | 1 |
| Tsunekawa, S | 1 |
| Taguchi, S | 1 |
| Eguchi, Y | 1 |
| Zeller, A | 1 |
| Battegay, E | 1 |
| Walden, M | 1 |
| Hillmann, M | 1 |
| Kaiser, T | 1 |
| Yusuf, S | 1 |
| Ostergren, JB | 1 |
| Gerstein, HC | 1 |
| Pfeffer, MA | 1 |
| Swedberg, K | 1 |
| Granger, CB | 1 |
| Olofsson, B | 1 |
| Probstfield, J | 1 |
| McMurray, JV | 1 |
| Song, JH | 1 |
| Cha, SH | 1 |
| Lee, HJ | 1 |
| Lee, SW | 2 |
| Park, GH | 1 |
| Kim, MJ | 1 |
| Kawata, T | 1 |
| Daimon, M | 2 |
| Hasegawa, R | 1 |
| Teramoto, K | 1 |
| Toyoda, T | 1 |
| Sekine, T | 1 |
| Yamamoto, K | 2 |
| Uchida, D | 1 |
| Himi, T | 1 |
| Yoshida, K | 1 |
| Komuro, I | 1 |
| Spoelstra-de Man, AM | 1 |
| Kamp, O | 1 |
| Brouwer, CB | 1 |
| Iwashima, Y | 1 |
| Okada, M | 1 |
| Haneda, M | 1 |
| Yoshida, T | 1 |
| Vegazo, O | 1 |
| Fernandez, R | 1 |
| Asín, E | 1 |
| Kawasaki, D | 1 |
| Kosugi, K | 1 |
| Waki, H | 1 |
| Tsujino, T | 1 |
| Masuyama, T | 1 |
| Ogawa, S | 1 |
| Takeuchi, K | 1 |
| Mori, T | 1 |
| Nako, K | 1 |
| Tsubono, Y | 1 |
| Ito, S | 1 |
| Lekakis, I | 1 |
| Liatis, S | 1 |
| Vamvakou, G | 1 |
| Zoumakis, E | 1 |
| Rabavilas, AD | 1 |
| Corradi, L | 1 |
| Zoppi, A | 1 |
| Lazzari, P | 1 |
| Preti, P | 1 |
| Rinaldi, A | 1 |
| Tsukuda, K | 1 |
| Mogi, M | 1 |
| Li, JM | 1 |
| Iwanami, J | 1 |
| Min, LJ | 1 |
| Sakata, A | 1 |
| Fujita, T | 1 |
| Iwai, M | 1 |
| Horiuchi, M | 1 |
| Yoneda, T | 1 |
| Takeda, Y | 1 |
| Usukura, M | 1 |
| Oda, N | 1 |
| Takata, H | 1 |
| Yamamoto, Y | 1 |
| Karashima, S | 1 |
| Yamagishi, M | 1 |
| Huang, Z | 1 |
| Jansson, L | 1 |
| Sjöholm, A | 1 |
| Neldam, S | 1 |
| Tikkanen, I | 1 |
| Oren, S | 1 |
| Viskoper, R | 1 |
| Watts, RW | 1 |
| Cooper, ME | 1 |
| Philips, JC | 1 |
| Weekers, L | 1 |
| Scheen, AJ | 1 |
| Igarashi, M | 1 |
| Hirata, A | 1 |
| Yamaguchi, H | 1 |
| Tsuchiya, H | 1 |
| Ohnuma, H | 1 |
| Tominaga, M | 1 |
| Preston, RA | 1 |
| Baltodano, NM | 1 |
| Alonso, AB | 1 |
| Epstein, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Angiotensin Converting Enzyme Inhibitors vs Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension[NCT01152567] | 50,000 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.[NCT00252694] | Phase 3 | 4,717 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.[NCT00252733] | Phase 3 | 5,238 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.[NCT00252720] | Phase 3 | 1,850 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area[NCT02834663] | Phase 4 | 25 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction[NCT04128891] | Phase 3 | 0 participants (Actual) | Interventional | 2020-02-01 | Withdrawn (stopped due to Funding not approved) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 161 |
| Placebo | 182 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 180 |
| Placebo | 136 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 192 |
| Placebo | 193 |
An estimate of the slope from fitting a linear regression of log(UAER) over time (post-randomisation, yearly assessments) for each patient. (NCT00252694)
Timeframe: From Baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/1000 year (Least Squares Mean) |
|---|---|
| Candesartan | 656 |
| Placebo | 718 |
Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 178 |
| Placebo | 217 |
An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.510 |
| Placebo | 0.543 |
Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 127 |
| Placebo | 124 |
Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252720)
Timeframe: From baseline to the end of the study, i.e., 5 years
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 140 |
| Placebo | 139 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 110 |
| Placebo | 107 |
An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.569 |
| Placebo | 0.642 |
CRT was performed using OCT at each visit. The OCT measured at each visit was analyzed statistically. the CMT compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | um (Mean) |
|---|---|
| CRT Baseline | 479.12 |
| CRT Resulte | 369.12 |
Using ImageJ software (version 1.52a) by FAG image. The Perifoveal non-perfusion area in FAG compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | mm2 (Mean) |
|---|---|
| Perifoveal Non-perfusion Area Baseline | 2.517 |
| Perifoveal Non-perfusion Area Results | 2.495 |
Systemic adverse events (MI, CVA, etc), Ocular adverse events (retinal detachment, RPE tear, endophthalmitis, uveitis, vitreous hemorrhage, subretinal hemorrhage, cataract , IOP elevation, etc) at baseline and each visit. (NCT02834663)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Safety Parameters Results | 0 |
BCVA was performed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at baseline and 6 months. The BCVA compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | letters (Mean) |
|---|---|
| BCVA Baseline | 67.6 |
| BCVA Resulte | 76.36 |
Number of MAs that resolved/month The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm disappearance rate compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms/month (Mean) |
|---|---|
| The MA Disappearance Rate Baseline | 4.40 |
| The MA Disappearance Rate Resulte | 0.96 |
number of new MAs detected/month The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm formation rate compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms/month (Mean) |
|---|---|
| The MA Formation Rate Baseline | 2.48 |
| The MA Formation Rate Resulte | 0.96 |
The microaneurysm formation rate + The microaneurysm disappearance rate The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm turnover compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms/month (Mean) |
|---|---|
| The Microaneurysm Turnover Baseline | 6.88 |
| The Microaneurysm Turnover Results | 1.92 |
The number of MAs in individual retinas were evaluated during 6 months using fundus photography and FA imaging. The Retmarker software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. Changes in MAs were analyzed statistically. the total number of MAs compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms (Mean) |
|---|---|
| Total MA Baseline | 5.68 |
| Total MA Resulte | 1.60 |
8 reviews available for candesartan and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 2017 |
[Anti-metabolic syndrome effects of candesartan].
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; D | 2009 |
Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2010 |
Cardio classics revisited--focus on the role of candesartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardi | 2010 |
Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2011 |
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2011 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
[Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Angiotensin II; Angiotensin II Ty | 2005 |
43 trials available for candesartan and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compounds; Cros | 2021 |
Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2014 |
Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co | 2008 |
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes M | 2008 |
Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Compo | 2008 |
Angiotensin II type-I receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Ankle Brachial Index; Benzimidazoles; Biphenyl Compou | 2008 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; | 2009 |
Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Candesartan effect on inflammation in hypertension.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood | 2010 |
Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Comp | 2010 |
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compou | 2010 |
Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabet | 2010 |
Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidaz | 2012 |
[Clinical implications from the results of the CASE-J extension].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Calcium Channel Bl | 2012 |
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aze | 2012 |
Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Anti | 2012 |
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cros | 2003 |
Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2003 |
A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compound | 2003 |
Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized c
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mell | 2005 |
Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus | 2005 |
Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2005 |
Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2005 |
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns.
Topics: Albuminuria; Amino Acid Sequence; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarker | 2005 |
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2005 |
The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type | 2005 |
Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2006 |
Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2006 |
Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Compliance | 2006 |
Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients--reversal by chronic angiotensin II type 1A receptor blockade.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2007 |
Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2007 |
Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results.
Topics: Adrenocorticotropic Hormone; Adult; Affect; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; | 2008 |
Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2007 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2007 |
Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2008 |
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimi | 2000 |
[Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy].
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimi | 2001 |
Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus.
Topics: Administration, Oral; Adult; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Con | 2002 |
29 other studies available for candesartan and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Candesartan protects against unilateral peripheral limb ischemia in type-2 diabetic rats: Possible contribution of PI3K-Akt-eNOS-VEGF angiogenic signaling pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Ischemia; Neovascularization, P | 2023 |
THE NITROSAMINE CONTAMINATION IN BETA BLOCKERS (BISOPROLOL/METOPROLOL), ACE INHIBITORS (LISINOPRIL/PERINDOPRIL), THIAZIDES DIURETICS (HCT), CALCIUM CHANNEL BLOCKERS (AMLODIPINE/FELODIPINE), SARTANS (CANDESARTAN) AND ТHE SUBSEQUENT SKIN CANCER DEVELOPMENT
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2023 |
Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report.
Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2013 |
Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; B | 2013 |
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2014 |
Chronic NF-κB blockade improves renal angiotensin II type 1 receptor functions and reduces blood pressure in Zucker diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2015 |
Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Com | 2017 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2008 |
DIRECT new treatments for diabetic retinopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabete | 2008 |
Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model.
Topics: Administration, Oral; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thora | 2008 |
Administration time difference of candesartin effect on albuminuria in type 2 diabetic patients.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2010 |
Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Topics: Age of Onset; Aged; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Blood | 2010 |
Effects of antihypertensive drugs in the prevention of new-onset diabetes mellitus in patients with hypertension at high-risk of cardiovascular events in relation to aging.
Topics: Age Distribution; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2010 |
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antipsychotic Agents; Benzimidazol | 2010 |
Cardiovascular protection with candesartan in patients with metabolic disorders.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2010 |
Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation.
Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; D | 2011 |
Drug repurposing for vascular protection after acute ischemic stroke.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl C | 2011 |
Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2013 |
Role of ANG II in coronary capillary angiogenesis at the insulin-resistant stage of a NIDDM rat model.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2002 |
Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cross | 2002 |
Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mell | 2003 |
American Diabetes Association--63rd Scientific Sessions. Preclinical data. 13-17 June 2003, New Orleans, LA, USA.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chemokine CCL2; Diabet | 2003 |
Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Body Weight; Di | 2004 |
Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug E | 2007 |
Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2007 |
Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2008 |
Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Carotid Artery, Commo | 2001 |